Results 101 to 110 of about 4,435,862 (297)
Direct oral anticoagulants in patients with cancer
AbstractPurposeThis review summarizes the available evidence concerning direct oral anticoagulant (DOAC) use to treat venous thromboembolism (VTE) in patients with cancer as well as pertinent safety data on the use of DOACs in patients with both cancer and atrial fibrillation.SummaryThe introduction of DOACs into clinical practice changed the way ...
Bossaer, John B., Covert, Kelly L.
openaire +3 more sources
Clinical Outcomes of Drug‐Eluting Stents and Drug‐Coated Balloons in Tortuous Small Coronary Lesions
ABSTRACT Background In small, tortuous coronary lesions, the long‐term comparative performance of drug‐coated balloon (DCB) angioplasty versus drug‐eluting stent (DES) treatment remains uncertain, despite both strategies being widely used in contemporary percutaneous coronary intervention (PCI) practice. Aims This study aimed to compare 3‐year clinical
Shunichiro Ishio +6 more
wiley +1 more source
ABSTRACT Background Transcatheter closure (TCC) of sinus venosus defects (SVD) using balloon‐expandable covered stents is an emerging alternative to surgery. ZephyrCS (Sahajanand Laser Technologies, Gandhinagar, India) is available in long lengths to suit SVD closure.
Pramod Sagar +3 more
wiley +1 more source
Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?
Laboratory monitoring of direct oral anticoagulants ...
LIPPI, Giuseppe, Favaloro, Emmanuel J.
core +1 more source
ABSTRACT Background Rotational atherectomy (RA) has undergone considerable technical modernization in recent years. This study evaluated whether RA performed in the contemporary era was associated with superior cardiovascular outcomes compared with the traditional era. Aims To compare the clinical characteristics and cardiovascular outcomes of patients
Ravi Vazirani +15 more
wiley +1 more source
Utilization and prescribing patterns of direct oral anticoagulants
Maegan M Whitworth,1 Krystal K Haase,1 David S Fike,1 Ravindra M Bharadwaj,2 Rodney B Young,3 Eric J MacLaughlin1,4 1Department of Pharmacy Practice, Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy, 2Department of Internal ...
Fike DS +5 more
core
Helen Mani, Edelgard Lindhoff-LastJohann Wolfgang Goethe-University Hospital Frankfurt/Main, Department of Internal Medicine, Division of Haemostasis, Frankfurt, GermanyAbstract: Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular
Lindhoff-Last E +3 more
core +1 more source
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul +5 more
wiley +1 more source
Direct oral anticoagulants and travel-related venous thromboembolism
Travel- related thromboembolism reflects the relationship between venous thromboembolism (VTE) and long-haul flights. Although this condition is rare, it may cause significant morbidity and mortality.
Chamnanchanunt Supat +1 more
doaj +1 more source
The purpose of this review is to examine the possibilities and prospects for the use of direct oral anticoagulants for the prevention of thromboembolic complications in patients with atrial fibrillation and chronic kidney disease.
V. I. Petrov +3 more
doaj +1 more source

